In a dramatic escalation of corporate tensions, activist investor Starboard Value has alleged that former Pfizer executives were threatened with legal action and financial penalties for initially supporting the fund's reform initiatives at the pharmaceutical giant.
The controversy emerged after former Pfizer CEO Ian Read and former CFO Frank D'Amelio abruptly announced their withdrawal from Starboard's efforts to reshape the company. In a statement released through Guggenheim Securities, both executives expressed their "full support" for current Chairman and CEO Albert Bourla, senior management, and the board.
According to Starboard's managing member Jeffrey Smith, the executives faced threats of "costly litigation, compensation clawbacks, and cancellation of unvested performance stock units" from individuals within or representing Pfizer. These allegations were detailed in a letter to Pfizer's board, though the company has declined to comment on the matter.
Strategic Stakes and Corporate Pressure
The confrontation follows Starboard's recent acquisition of a $1 billion stake in Pfizer, representing a significant position in the pharmaceutical company. Before their withdrawal, Read and D'Amelio had reportedly shared concerns about Pfizer's business trajectory and had even reached out to current board members, encouraging them to consider Starboard's perspective.
Pfizer's Current Challenges
The activist investor's interest comes at a critical juncture for Pfizer, which faces multiple operational and strategic challenges:
- The company's stock has lost approximately half its value since late 2021
- COVID-19 vaccine revenue has significantly declined from pandemic peaks
- Recent setbacks include falling behind in the obesity drug market
- The withdrawal of a sickle cell disease treatment from the market
- Discontinuation of a gene therapy program for Duchenne muscular dystrophy
- Looming patent expirations for key products, including the blood thinner Eliquis
Path Forward
Despite the contentious situation, Starboard's Smith has indicated a willingness to work constructively with Pfizer's leadership. A meeting between Starboard and CEO Bourla is scheduled for October 16, potentially including board members. The activist investor has also requested the formation of a special committee to investigate the alleged coercion of the former executives.
Pfizer's current strategy focuses on strengthening its cancer drug pipeline and implementing cost-cutting measures. However, Starboard has expressed concerns about the company's use of COVID-19 windfall profits, particularly regarding recent acquisitions.
The situation remains fluid, with Starboard's specific demands for change at Pfizer yet to be fully articulated. This development adds another layer of complexity to Pfizer's ongoing efforts to navigate post-pandemic challenges and maintain its position in the pharmaceutical industry.
